Effect of C-Peptide on Diabetic Peripheral Neuropathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of the study is to investigate the effect of C-peptide administration on nerve function in patients with type 1 diabetes and peripheral sensory neuropathy.
Condition or disease
Diabetes Mellitus, Type 1Diabetic Polyneuropathy
It has been observed that C-peptide administration results in an activation of renal tubular and sciatic endoneural Na/K-ATPase of the rat and stimulation of endothelial nitric oxide synthase. The hypothesis is that C-peptide administration may improve peripheral nerve dysfunction in diabetic neuropathy by increasing nerve blood flow and Na/K-ATPase activity. The purpose of the trial is to investigate the effect of C-peptide administration on diabetic peripheral sensory neuropathy in patients with type 1 diabetes and diabetic neuropathy in the lower extremities.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects who have a duration of type 1 diabetes of more than 5 yrs
Subjects who are C-peptide deficient
Subjects who have diabetic distal symmetric neuropathy, according to the criteria defined at the San Antonio Conference on Diabetic Neuropathy 1988
Subjects who have measurable action potential in the sural nerves
Subjects who have reduced nerve conduction velocity in the sural nerves
Subjects who have neuropathy or signs of nerve dysfunction which may be a consequence of factors other than type 1 diabetes
Subjects who have concomitant medication that may interfere with the peripheral nerve function or measurement thereof
Subjects who are transplanted (islet cell, kidney or pancreas)